Midlands & Wales Advanced Therapy Treatment Centre (MW-ATTC)
Lead Participant:
UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST
Abstract
"ATMPs, which can be _cell or gene therapies_, show great potential in treating patients with conditions that cannot be cured with current treatments. These include arthritis, liver disease, several types of cancer, and diabetic ulcers.
ATMPs are just beginning to be available, with the UK playing a leading role. However, even when new ATMP therapies are developed and shown to be effective, there are **major challenges in rolling them out to patients**. The reasons for this include: complexities in transporting a 'living' product, and lack of familiarity with such products in most NHS hospitals.
The project lead is the Birmingham Biomedical Research Centre, a national centre of excellence. The Welsh government has also made a major investment in cell therapy and is supportive of NHS Wales as the joint-lead on this project. We are a **team of industrialists, clinicians, academics and computer system experts** who have all the necessary skills to succeed in this project.
Our group **covers the Midlands and Wales** giving us access to major teaching hospitals and almost 15 million people providing a unique opportunity to set cell therapy up to succeed.
We will:
-Set up a network of hospitals with medical staff trained to receive and administer ATMPs.
-Build seamless supply chains that ensure that 'living medicines' remain healthy and effective as they are moved from the production laboratory to the bedside.
-Put in place the IT systems to manage the end-to-end process.
-Validate this new infrastructure using real ATMPs
-Deliver a programme that uses this infrastructure to speed up the testing of ATMPs in clinical trials.
-Set-up protocols to test whether the **cost of a new ATMP is justified by its clinical effectiveness.**
The benefits of MW-ATTC are (a) Patients with challenging illnesses will get access to breakthrough medicines; (b) ATMP companies will get access to the clinical mainstream and market; (c) Investment in this important industry sector will increase, as we demonstrate that the UK is an excellent location for ATMP R&D. MW-ATTC will be one of three Advanced Therapy Treatment Centres in the UK, working together for patients and ATMP innovators, to reinforce the UK's position as a world leader in this important field."
ATMPs are just beginning to be available, with the UK playing a leading role. However, even when new ATMP therapies are developed and shown to be effective, there are **major challenges in rolling them out to patients**. The reasons for this include: complexities in transporting a 'living' product, and lack of familiarity with such products in most NHS hospitals.
The project lead is the Birmingham Biomedical Research Centre, a national centre of excellence. The Welsh government has also made a major investment in cell therapy and is supportive of NHS Wales as the joint-lead on this project. We are a **team of industrialists, clinicians, academics and computer system experts** who have all the necessary skills to succeed in this project.
Our group **covers the Midlands and Wales** giving us access to major teaching hospitals and almost 15 million people providing a unique opportunity to set cell therapy up to succeed.
We will:
-Set up a network of hospitals with medical staff trained to receive and administer ATMPs.
-Build seamless supply chains that ensure that 'living medicines' remain healthy and effective as they are moved from the production laboratory to the bedside.
-Put in place the IT systems to manage the end-to-end process.
-Validate this new infrastructure using real ATMPs
-Deliver a programme that uses this infrastructure to speed up the testing of ATMPs in clinical trials.
-Set-up protocols to test whether the **cost of a new ATMP is justified by its clinical effectiveness.**
The benefits of MW-ATTC are (a) Patients with challenging illnesses will get access to breakthrough medicines; (b) ATMP companies will get access to the clinical mainstream and market; (c) Investment in this important industry sector will increase, as we demonstrate that the UK is an excellent location for ATMP R&D. MW-ATTC will be one of three Advanced Therapy Treatment Centres in the UK, working together for patients and ATMP innovators, to reinforce the UK's position as a world leader in this important field."
Lead Participant | Project Cost | Grant Offer |
|---|---|---|
| UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST | £1,583,239 | £ 1,583,239 |
Participant |
||
| ASYMPTOTE LIMITED | £773,549 | £ 386,775 |
| INSTIL BIO (UK) LIMITED | £965,936 | £ 676,155 |
| NHS BLOOD AND TRANSPLANT | £190,938 | £ 190,938 |
| NHS BLOOD AND TRANSPLANT (NHSBT) | ||
| UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST | ||
| NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST | ||
| INNOVATE UK | ||
| NOTTINGHAM UNI HOSPITALS NHS TRUST | £156,772 | £ 156,772 |
| INSTIL BIO (UK) LTD | ||
| ORBSEN THERAPEUTICS UK LTD | £1,467,008 | £ 1,026,906 |
| THERMO ELECTRON LIMITED | £178,854 | £ 107,312 |
| VELINDRE NHS TRUST | £1,699,023 | £ 1,699,023 |
| ASTON UNIVERSITY | ||
| UNIVERSITY OF BIRMINGHAM | £1,851,945 | £ 1,851,945 |
| IXAKA LIMITED | £474,877 | £ 332,414 |
| NATIONAL INSTITUTE FOR HEALTH RESEARCH BIRMINGHAM BIOMEDICAL RESEARCH CENTRE | ||
| WORLD COURIER LOGISTICS (UK) LIMITED | £149,528 | £ 74,764 |
| INNOVATE UK | ||
| TRAKCEL LIMITED | £774,786 | £ 542,350 |
People |
ORCID iD |
| Nisha Sungum (Project Manager) |